Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation

Nam Hoon Kwon\textsuperscript{a}, Mi Ran Lee\textsuperscript{a}, Jiwon Kong\textsuperscript{ab}, Seung Kyun Park\textsuperscript{c}, Byung Joon Hwang\textsuperscript{d}, Byung Gyu Kim\textsuperscript{a}, Eun-Shin Lee\textsuperscript{d}, Hyeong-Gon Moon\textsuperscript{d,e}, and Sunghoon Kim\textsuperscript{a,\textasteriskcentered e}

\textsuperscript{a}Medicinal Bioconvergence Research Center, Seoul National University, Suwon, Gyeonggi, Korea; \textsuperscript{b}Department of Pharmacy, Seoul National University, Seoul, Korea; \textsuperscript{c}Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University, Chunchon, Kangwon, Korea; \textsuperscript{d}Department of Surgery, Seoul National University College of Medicine, Seoul, Korea; \textsuperscript{e}Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Converging Science and Technology, Seoul National University, Suwon, Gyeonggi, Korea

ABSTRACT

While transfer-RNAs (tRNAs) are known to transport amino acids to ribosome, new functions are being unveiled from tRNAs and their fragments beyond protein synthesis. Here we show that phosphorylation of 90-kDa RPS6K (ribosomal proteins S6 kinase) was enhanced by tRNA\textsubscript{Leu} overexpression under amino acids starvation condition. The phosphorylation of 90-kDa RPS6K was decreased by siRNA specific to tRNA\textsubscript{Leu} and was independent to mTOR (mammalian target of rapamycin) signaling. Among the 90-kDa RPS6K family, RSK1 (ribosomal S6 kinase 1) and MSK2 (mitogen-and stress-activated protein kinase 2) were the major kinases phosphorylated by tRNA\textsubscript{Leu} overexpression. Through SILAC (stable isotope labeling by/with amino acids in cell culture) and combined mass spectrometry analysis, we identified EBP1 (ErbB3-binding protein 1) as the tRNA\textsuperscript{Leu}-binding protein. We suspected that the overexpression of free tRNA\textsuperscript{Leu} would reinforce ErbB2/ErbB3 signaling pathway by disturbing the interaction between ErbB3 and EBP1, resulting in RSK1/MSK2 phosphorylation, improving cell proliferation and resistance to death. Analysis of samples from patients with breast cancer also indicated an association between tRNA\textsuperscript{Leu} overexpression and the ErbB2-positive population. Our results suggested a possible link between tRNA\textsuperscript{Leu} overexpression and RSK1/MSK2 activation and ErbB2/ErbB3 signaling.

Introduction

Transfer-RNAs (tRNAs), aminoacyl-tRNA synthetases (ARSs), and amino acids are the essential elements for protein synthesis. ARSs ligate tRNAs with cognate amino acids, after which aminoacyl-tRNAs participate in translation, transporting precursor amino acids to the ribosome.\textsuperscript{1} Although one tRNA is usually charged with only one of the 20 different amino acids, the human tRNA\textsubscript{ome} is very complicated, and consists of more than 500 interspersed tRNA genes and 51 anticodon families.\textsuperscript{2} Most tRNA groups incorporate isoacceptors that are charged with the same amino acid, but have different anticodons. In addition, sequence similarities do not guarantee the equal function or expression of tRNAs.\textsuperscript{3,4}

For a long time, tRNAs have been considered as merely house-keeping RNAs; however, recent studies have suggested that tRNAs and their fragments may have diverse roles. For example, Mey et al. had reported that several tRNAs could bind to cytochrome C, inhibiting caspase activation and cell apoptosis upon apoptotic stimuli.\textsuperscript{5} Initiator tRNAs are unique in that they can initiate translation; overexpression of initiator tRNAs was reported to change the translational efficiency of specific genes and alter the global tRNA expression, resulting in cell proliferation, enhanced cancer metastasis, and invasion.\textsuperscript{6,7} Various stimuli have been reported to cause tRNA digestion, generating small tRNA-derived fragments (tRFs).\textsuperscript{8} tRFs can be derived from pre-tRNAs or mature tRNAs and are similar in size to microRNAs. Our understanding of the diverse functions of tRFs has improved recently; tRFs are now known to participate in translation regulation, neuroprotection, cell proliferation, tumorigenesis, and RNA silencing similarly to microRNAs.\textsuperscript{9-13}

In addition, overexpression of tRNAs has been observed in various cancer cell lines and tissues, although their biogenesis and translational requirements remain obscure.\textsuperscript{4,14,15} Given that tRNA abundance is correlated with protein synthesis,\textsuperscript{16} it has been hypothesized that tRNA content may affect the rate of translation, globally or for a subset of proteins based on codon usage.\textsuperscript{17} A recent study had revealed that breast cancer metastasis was promoted by tRNA\textsubscript{Glu}\textsuperscript{UCU} and tRNA\textsubscript{Arg}\textsuperscript{CCG}.\textsuperscript{4} This study demonstrated that overexpression of specific tRNAs could modulate protein expression in a codon-dependent manner, resulting in metastatic behavior. It also shed light on the importance of quantitative changes in tRNAs. However, it is still debated whether tRNA abundance and codon usage are under concerted regulation of translation rate and efficiency.\textsuperscript{18-20} In fact, several studies have suggested that preferentially used...
codons are not translated faster, and that tRNA variation might play an adaptive role in coping with environmental changes. Analysis of human tRNAs using microarrays have revealed that tRNAs could be biasedly induced toward different cell programs such as proliferation and differentiation.\(^{20,21}\) Taken together, these reports suggested that more studies would be required for understanding the relationship between tRNAs and translational need.

The ribosomal protein S6 kinase (RPS6K) is a family of proteins which have the ability to phosphorylate a 40S ribosomal subunit component and mediate key intracellular signaling.\(^{22}\) RPS6K shares a hydrophobic motif and representative phosphorylation site among the family members and it comprises 4 RSKs (ribosomal S6 kinases, RSK1–4), 2 MSks (mitogen-and stress-activated protein kinases, MSK1–2), S6K1 and S6K2 proteins.\(^{23,24}\) Among them, p70 S6K and p85 S6K are two splice isoacceptors, tRNA\(^{\text{Leu}}\) (Fig. 1C) on cell proliferation, we wondered whether the overexpression of these tRNAs would be common among the isoacceptors. We transfected 4 different amino acids, and tRNA\(^{\text{Leu}}\), tRNA\(^{\text{Met}}\), tRNA\(^{\text{Leu}}\), and tRNA\(^{\text{Met}}\) only when leucine was absent (Fig. 2C). The absence of amino acids was not a cue for the transcriptional induction of tRNAs (Fig. S2B), indicating that the effect of tRNA\(^{\text{Leu}}\) had originated from the already overexpressed free tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\). All these data emphasized again that free surplus tRNAs had the ability to induce p90 protein phosphorylation in the absence of amino acids, and tRNA\(^{\text{Leu}}\) was the most sensitive responder or the strongest inducer.

We wondered whether the observed effect of tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) would be common among the isoacceptors. We transfected 4 different tRNA\(^{\text{Leu}}\) isoacceptors, tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\), tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\), and tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) and tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) and examined p90 protein phosphorylation. All tRNA\(^{\text{Leu}}\) isoacceptors were found to enhance the phosphorylation, although tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) seemed to have the least effect (Fig. 2D). We next designed siRNAs (small interfering RNA) specific to tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) (si-Leu) and introduced them sufficient nutrition conditions, even under serum-free (SF) conditions (Fig. 1C). Very little difference was observed among the tRNA isotypes. However, under amino acid starvation, the isotypes of the overexpressed tRNAs seemed to have different effects on the resistance of cells to death: the cells overexpressing tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) showed the highest viability (Fig. 1C). Based on the expression levels of tRNA investigated by qRT-PCR (Table S2, Fig. S1B), the highest expression level did not correspond to the highest cell viability, suggesting that the effect on cell proliferation was unique for each tRNA isotype.

### Results

**tRNA\(^{\text{Leu}}\) overexpression promotes cell proliferation**

We cloned genomic DNA fragments containing the representative tRNAs into the pGEM-T Easy vector (Table S1 and S2). The fragments contained at least 200 bp each upstream and downstream of the endogenous tRNA gene, which included all the regulatory elements necessary for tRNA transcription.\(^{26,27}\) We transfected several tRNA vectors into mammalian cells and confirmed the overexpression of these tRNAs via RT-PCR (Fig. S1A). As many studies have reported novel functions of tRNAs or tRFs in cell proliferation or apoptosis,\(^{5-7,10,11,28,29}\) we wondered whether the overexpression of these tRNAs would affect any cell phenotypes. Interestingly, the overexpression of tRNAs enhanced cell proliferation, based on [\(^{3}H\)]thymidine incorporation and cell number count; tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) was found to show the most significant effects (Fig. 1A). Protein synthesis, measured by [\(^{35}\)S]Met incorporation, also showed significant changes after the overexpression of tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) and tRNA\(^{\text{Met}}\)\(_{\text{CAG}}\), but not so much as cell proliferation (Fig. 1A). The results of cell cycle analysis also supported those of \(^{3}H\)thymidine incorporation and cell number count, showing increased S-phase upon overexpression of tRNA\(^{\text{Leu}}\)\(_{\text{CAG}}\) (Fig. 1B).

As there are at least 20 tRNA isotypes that are charged by different amino acids, we compared the effect of overexpression of the different tRNA isotypes. We transfected each tRNA isoacceptor into cells and monitored the cell growth in real time using the Incucyte Live Cell Analysis System. All the HEK 293T cells transfected with the different tRNA isotypes showed enhanced proliferation, compared with the negative control, under
into the tRNA<sub>Leu</sub><sup>CAG</sup>-overexpressing cells. Treatment with si-Leu reduced the tRNA<sub>Leu</sub><sup>CAG</sup>-mediated phosphorylation in response to amino acid deprivation, but was not effective in the presence of amino acids (Fig. 2E), suggesting that tRNA<sub>Leu</sub><sup>CAG</sup> was not a major inducer for p90 protein phosphorylation in the presence of amino acids. We synthesized tRNA<sub>Leu</sub><sup>CAG</sup> through in vitro transcription, and performed native PAGE (polyacrylamide gel electrophoresis) after incubating tRNA<sub>Leu</sub><sup>CAG</sup> with si-Leu and si-control RNAs. tRNA<sub>Leu</sub><sup>CAG</sup> formed a complex only with si-Leu, resulting in a size shift (Fig. 2F), suggesting that si-Leu treatment might have disturbed the generation of mature tRNA<sub>Leu</sub><sup>CAG</sup> or the formation of secondary structures in the cells; however, we still do not know whether it induced tRNA decay via conventional RNA-degrading pathways. We compared tRNA<sub>Leu</sub><sup>CAG</sup> with other tRNAs and confirmed that tRNA<sub>Leu</sub><sup>CAG</sup> was the most efficient in inducing p90 protein phosphorylation (Fig. S2C & S2D).

**Mature tRNA<sub>Leu</sub> increases the phosphorylation of 90-kDa RPS6K, and it is independent of mTOR activation**

As many studies have suggested different functions of tRFs, we performed northern blotting to check whether the overexpression of tRNA<sub>Leu</sub> would generate corresponding fragments. We used 30-bp radioactive probes to detect the 3 mature isoacceptors of tRNA<sub>Leu</sub> as well as their 3′ and 5′ end-derived fragments. As shown in Fig. 3A, a short exposure revealed the overexpression of tRNA<sub>Leu</sub>, compared

**Figure 1.** Overexpression of tRNAs enhanced the cell proliferation. (A) Relative levels (percentage) of cell number, thymidine incorporation, and methionine incorporation after overexpression of each tRNA were compared with those in EV (empty vector)-transfected control. Values are presented as means ± standard deviations (n = 3). *, P < 0.05; ***, P < 0.001. (B) Change in cell cycle after tRNA transfection was compared with that in control. (C) Real-time proliferation of HEK 293T cells transfected with different tRNAs was monitored under different culture conditions. Values are presented as means ± standard errors (n = 9). Values for tRNA<sub>Leu</sub>CAG and negative control (NC) are repeated in all the graphs for the comparison. Cell viability was calculated as the relative percentage of confluence. CM, complete media; SF, serum free; AA, amino acids.
with the EV-transfected cells. After a long exposure, we detected the 3'0 and 5'0 fragments of each tRNA in the HeLa cells used as positive controls for tRF detection. However, only very little difference was observed in the detectable tRFs in the HEK 293T cells, regardless of tRNA\textsubscript{Leu} overexpression (Fig. 3A).

These results indicated that the transfection of tRNA vectors generated a sufficient amount of mature tRNA\textsubscript{Leu} without digestion, and this mature tRNA\textsubscript{Leu} functioned as inducers for the p90 protein phosphorylation.

Next, we investigated the possible relationship between tRNA\textsubscript{Leu}\textsubscript{CAG} and LRS, as well as mTOR. Knockdown of LRS did not affect the level of tRNA\textsubscript{Leu}-induced p90 protein phosphorylation (Fig. 3B). When rapamycin, an mTOR inhibitor, was added to the tRNA\textsubscript{Leu}-overexpressing cells, the level of p90 protein phosphorylation was not reduced (Fig. 3C). These results suggested that p90 protein phosphorylation required the overexpression of mature tRNA\textsubscript{Leu}, and this step was not controlled by LRS or mTOR.

**RSK1 and MSK2 are the p90 RPS6K whose phosphorylation was induced by tRNA\textsubscript{Leu} overexpression**

Endogenous S6K1 exists in two isoforms, p70 S6K and p85 S6K. Initially, we assumed that the p90 protein that we were monitoring was the p85 S6K; however, we had to rule out p85 S6K due to its reactivity to mTOR, unlike the p90 protein.
of our interest. While searching for other candidates, we came upon a report on RSK and MSK. The authors had detected RSK phosphorylation at S380 by an anti-phosphorylation antibody specific to p70 S6K (Fig. 4A). They also investigated the induction of phosphorylation of RSK and MSK under amino acid supplementation, although they did not consider the effect of tRNA overexpression.

As mentioned before, RSK and MSK are one of the RPS6K, and are activated by ERK (extracellular signal-regulated kinases) and p38 MAPK (mitogen-activated protein kinase). Therefore, we investigated the activation of ERK as well as the effect of ERK and p38 MAPK inhibitors on the p90 protein phosphorylation. ERK was activated in the presence of surplus tRNAs (Fig. 4B, C). The tRNA\textsuperscript{Leu}\textsuperscript{m}}-mediated p90 protein phosphorylation was blocked by ERK and p38 MAPK inhibitors, but not by the JNK inhibitor (Fig. 4D).

There were seven candidate proteins for the p90 RPS6K based on the size and sequence homology (Fig. 4A). We transfected p85 S6K, 4 RSKs, and 2 MSKs into HEK 293T cells, along with tRNA\textsuperscript{Leu}\textsuperscript{m}}\textsuperscript{CAG}, and monitored their levels of phosphorylation. We found that p85 S6K, RSK1, and MSK2 were ideal candidates for the p90 protein; the tRNA\textsuperscript{Leu}\textsuperscript{m}}-mediated activation of these proteins was confirmed by detection with specific antibodies (Fig. 4E). Although p90 protein phosphorylation was detected in RSK2-transfected cells, it was not detected with antibodies specific to RSK phosphorylation (P-RSK); therefore, we excluded it from serious consideration. We knocked down p85 S6K, RSK1, RSK2, and MSK2 using siRNAs and confirmed that p85 S6K, RSK1, and MSK2 were the real effectors of tRNA\textsuperscript{Leu}\textsuperscript{m}} overexpression (Fig. 4F & 4G). We used two different sequences of siRNA for the specific depletion of RSK2; neither of them worked well, resulting in very little knockdown effect on RSK2 protein level; we were therefore forced to postpone our conclusion for RSK2.

Taken together, these results suggested that p85 S6K, RSK1, and MSK2 were the p90 proteins whose phosphorylation was induced by tRNA\textsuperscript{Leu}\textsuperscript{m}} overexpression. Considering that tRNA\textsuperscript{Leu}\textsuperscript{m}}-mediated phosphorylation was not affected by mTOR, RSK1 and MSK2 seemed to be the major effectors, rather than p85 S6K.

**EBP1 (ErbB3-binding protein 1) is the binding partner of uncharged tRNA\textsuperscript{Leu}\textsuperscript{m}}**

Overexpression of tRNA\textsuperscript{Leu}\textsuperscript{m}} also increased the phosphorylation of ERK, an upstream regulator of RSK, implying that tRNA\textsuperscript{Leu}\textsuperscript{m}}...
had a role in the upper region of the signal cascade. To understand how tRNA\textsubscript{Leu} mediated RSK1 and MSK2 signaling, we performed SILAC (stable isotope labeling by/with amino acids in cell culture) and mass spectrometry analysis to identify the tRNA\textsubscript{Leu}-interacting proteins. For this, we synthesized human tRNA\textsubscript{Leu}CAG in vitro and tagged it with biotin-Phe-DBE (dinitrobenzyl ester) using \textit{fl}exizyme.\textsuperscript{40} We prepared cell lysates under amino acid starvation, mixed it with the biotinylated tRNA\textsubscript{Leu}CAG, and incubated them together (Fig. 5A). Among the co-immunoprecipitated proteins analyzed with LC-MS/MS (liquid chromatography-tandem mass spectrometry) (Table 1), we were interested in EBP1, because it was the most enriched protein in the tRNA\textsubscript{Leu}-protein complex except for the RNA helicase-similar protein and it is known to be an RNA/DNA binding protein as well as an ErbB3-binding protein.\textsuperscript{41-43} To confirm the data obtained from mass spectrometry, we immunoprecipitated EBP1 from the HEK 293T cell lysates harvested after amino acid starvation, and then isolated bound RNAs from the immunoprecipitated beads. We detected several tRNAs from the purified RNA through RT-PCR and qRT-PCR in 2 independent experiments (Fig. 5B and Fig. S3), proving that EBP1 could interact with tRNAs. We investigated direct interactions between EBP1 and radioactively synthesized tRNA\textsubscript{Leu}CAG through non-denaturing PAGE. EBP1 and tRNA\textsubscript{Leu}CAG formed a complex, showing a size-shifted band in a dose-dependent manner (Fig. 5C).

EBP1 is a DNA- and RNA-binding protein that induces cell cycle arrest by suppressing the transcription of proliferation-associated genes.\textsuperscript{41} It also suppresses ErbB3 when EBP1 binds to it.\textsuperscript{42} ErbB3 is an epidermal growth factor receptor (EGFR), and is activated by various growth signals and other EGFR family proteins such as ErbB2. The interactions between EBP1 and ErbB3 are disrupted by the ErbB ligand, heregulin, causing nuclear translocation of EBP1.\textsuperscript{44} In addition, the
overexpression of EBP1 disrupts the ErbB2 and ErbB3 heterodimer, resulting in the inhibition of heregulin-mediated proliferation. \(^{44}\) Interestingly, RSK and MSK are downstream molecules of ErbB2 and ErbB3 signaling pathway, and heregulin causes increased or prolonged signaling through AKT, ERK, RSK, and MSK cascades. \(^{39,42}\) RSK and MSK were phosphorylated by tRNA\(^{\text{Leu}}\) overexpression, without growth stimuli such as serum or amino acids. We therefore hypothesized that free tRNA\(^{\text{Leu}}\) could induce the disruption of the interaction between EBP1 and ErbB3, leading to the inactivation of ErbB3 and/or ErbB2. To verify this, we used the MCF10A cell line which expresses endogenous ErbB2 and ErbB3.\(^{45}\) As expected, the phosphorylation of ErbB3, AKT, ERK, RSK, and MSK were all strongly induced by tRNA\(^{\text{Leu}}\) overexpression under amino acid starvation (Fig. 5D), indicating a possible link between tRNA\(^{\text{Leu}}\)-EBP1-ERBB3 and RSK/MSK.

Table 1. LC-MS/MS analysis of tRNA\(^{\text{Leu}}\) binding proteins.

| Description                                      | Ratio (Heavy/Light) |
|--------------------------------------------------|---------------------|
| cDNA FLJ53073, very similar to spliceosome RNA   | 11.138              |
| helicase Bat1                                    |                     |
| EBP1                                             | 2.123               |
| Isoform 2 of nucleolar RNA helicase 2            | 2.068               |
| Uncharacterized protein                          | 1.866               |
| Heterogeneous nuclear ribonucleoprotein R isom 4 | 1.810               |
| Electron transfer flavoprotein subunit \(\alpha\) | 1.703               |
| mitochondrial                                    |                     |
| Uncharacterized protein                          | 1.696               |
| Uncharacterized protein                          | 1.655               |
| High mobility group protein B2                   | 1.650               |
| Importin-7                                       | 1.646               |

Proteins associated with tRNA\(^{\text{Leu}}\) were identified via LC-MS/MS analysis. The 10 top-ranked proteins among the most enriched ones in amino acid starvation (Heavy) relative to serum-free conditions (Light) are presented.

Stable overexpression of tRNA\(^{\text{Leu}}\) and its correlation to Her2 (ErbB2)-positive breast cancer

We prepared NIH3T3 MEF (mouse embryonic fibroblast) cells that stably overexpressed tRNA\(^{\text{Leu}}\) to check whether the...
effects of tRNA^{Leu} CAG were persistent. We used a site-specific recombinase technology to introduce ectopic tRNA^{Leu} CAG into the genomic region. Thus, the selection marker, blasticidin, of EV was replaced with a cassette containing hygromycin (selection marker) and tRNA^{Leu} CAG, ruling out the variations caused by random insertions. The stable tRNA^{Leu} CAG-expressing cell line showed faster growth and resistance to cell death than the stable EV-expressing cell line under normal as well as amino acid-depleted conditions (Fig. 6A, Fig. S4A & S4B). The investigation of the signaling pathway also revealed that the stable expression of tRNA^{Leu} CAG induced RAF, ERK, and p38 MAPK activation, as well as RAS/MSK activation under amino acid starvation (Fig. 6B, C). It is worth noting that the tRNA^{Leu} CAG-expressing stable cell line was becoming increasingly more dependent on RSK activation, even under normal conditions such as complete medium (CM) culture conditions (Fig. 6C).

RSK and MSK signaling is important for the maintenance and the malignancy of breast cancer, prostate cancer, and lung cancer, and its upstream molecules, ErbB2 and ErbB3, are also
implicated in the causation or sustenance of various cancers, especially breast cancer.\textsuperscript{38,42,47} We therefore investigated the tRNA\textsuperscript{Leu} expression levels in normal and cancer cell lines, based on the tissue origin. According to the results, almost all tRNA-\textsuperscript{Leu} isoacceptors tested were more highly expressed in cancer cell lines than in normal cells, irrespective of the tissue type (Fig. 6D). We chose 2 breast cancer cell lines, MCF7 and BT20, and investigated the activation statuses of RSK and MSK. Interestingly, MCF7, with higher levels of tRNA\textsuperscript{Leu} isoacceptors, showed stronger phosphorylation of RSK and MSK than BT20 (Fig. 6E).

To investigate the possible implications of tRNA\textsuperscript{Leu} for human cancers, we analyzed the expression levels of tRNA\textsuperscript{Leu} isoacceptors in 95 samples from patients with breast cancer. We investigated the correlation between tRNA\textsuperscript{Leu} expression and breast cancer subtypes, expecting the upregulation of tRNA\textsuperscript{Leu} in Her2\textsuperscript{+} (ErbB2)-positive breast cancers. ErbB3 usually forms a heterodimer with ErbB2, with a positive correlation between the two molecules,\textsuperscript{48} and overexpression of tRNA\textsuperscript{Leu} might contribute to the strength of the ErbB2 signaling. Based on the analysis, tRNA\textsuperscript{Leu} isoacceptors such as tRNA\textsuperscript{Leu}_{CAA}, tRNA\textsuperscript{Leu}_{AAG}, and/or tRNA\textsuperscript{Leu}_{UAG} were significantly increased in the Her2 subtype, but not in other subtypes (Table 2). tRNA\textsuperscript{Leu}_{AAG} and tRNA\textsuperscript{Leu}_{UAG} could not be distinguished, because the same primers detected both isoacceptors simultaneously. This result suggested the possibility that tRNA\textsuperscript{Leu} overexpression might be implicated in ErbB2-mediated tumourigenesis via interacting with EBP1 and subsequently activating the RSK1/MSK2 signaling (Fig. 7).

**Discussion**

Recent studies have revealed the diverse roles of tRNAs and their related fragments, extending the functions of tRNAs beyond that of the canonical translation adaptor molecules.\textsuperscript{49} These new roles of tRNAs have been observed in prokaryotes as well as eukaryotes, and they are involved in various cellular phenomena, including haeme and chlorophyll biosynthesis, antibiotic cellular permeability, energy metabolism, amino acid biosynthesis and protein degradation, reverse transcription of viruses, cell apoptosis and survival, and cancer progression.\textsuperscript{4-6,10,37,50-55} In this study, we investigated the novel functions of tRNAs, especially tRNA\textsuperscript{Leu}, which promoted cell proliferation via RSK/MSK signaling.

Overexpression of tRNA\textsuperscript{Leu} enhanced cell proliferation under amino acid starvation. Given that amino acids are essential for normal cell growth, it is an obscure result. Our data indicated that amino acid starvation would determine the uncharged status of tRNA\textsuperscript{Leu}, rather than induce cell proliferation in itself, because the activation of RSK/MSK in this condition was independent of mTOR or LRS (Fig. 3B, C). We speculated that the overexpression of tRNA\textsuperscript{Leu} would gradually induce the activation of RSK/MSK due to amino acid depletion, even under complete media conditions. As there are many signaling pathways to activate RSK/MSK apart from free tRNAs, it is not surprising that RSK/MSK was phosphorylated when amino acids were added back in the medium, irrespective of tRNAs. Upon re-addition of amino acids, there would be enough tRNAs but they would be dedicated to translation, due to the prolonged starvation period (3 h). This may explain why we could not observe the effect of overexpressed tRNAs in the presence of amino acids.

It is interesting that the transfection of a single tRNA induced such a strong signal transduction and cell phenotype change, when there are more than 500 tRNA genes.\textsuperscript{2} Other research groups have also reported dramatic and significant effects of single tRNA transfection,\textsuperscript{4,6} and we confirmed the same results in stable NIH3T3 MEF cells, where a single copy of tRNA\textsuperscript{Leu}_{CAG} was inserted in the genomic region (Fig. 6A-C and Fig. S4). This result demonstrated that each copy of the tRNA gene might be essential (for some currently unknown reason), despite seemingly appearing overlapped and redundant with each other. However, the
activation of RSK and MSK signaling did not seem to be a unique function of tRNA_Leu, considering that other tRNA isotypes tested also induced the phosphorylation, although in different degrees (Fig. 2A, B). EB1P, a tRNA_Leu_CAG-binder, also interacted with several tRNAs besides tRNA_Leu (Fig. 5B and Fig. S3). EB1P has Lysine-rich motif in the C-terminal RNA/DNA-binding domain and seems to interact with various RNAs and DNAs, as observed in this study. While all the tRNAs share a similar clover-leaf-like secondary structure, eukaryotic tRNA_Leu and tRNA_Ccam have a long variable arm with more than 10 nucleotides, and these are designated as class II tRNAs. The differences in structure and sequence length of tRNA_Leu might contribute to the interaction with EB1P and explain why tRNA_Leu was the strong inducer for the phosphorylation of RSK and MSK, while other tRNAs were not. One or more additional factors, however, seem to be required for the signaling induction, considering that the activation of RSK and MSK was not very responsive to tRNA overexpression (Fig. S2C). The interaction between tRNA_Leu and EB1P, and their working mechanism need to be further elucidated.

In conclusion, we suggested that free tRNA_Leu had a novel function in enhancing RSK and MSK signaling via interaction with EB1P. EB1P is known to be an ErbB3 suppressor, and our data indicated that tRNA_Leu overexpression reinforced the ErbB2/ErbB3 pathway. It is worth noting that the expression of several tRNA_hum isoacceptors was significantly high in ErbB2-positive patients with breast cancer (Table 2). The factor that induced the expression of tRNA_Leu in ErbB2-positive breast cancers is unclear; however, this observation suggested a possible contribution by tRNA_Leu to the malignancy of ErbB2-positive breast cancer.

Materials and methods

**tRNA cloning and antibodies**

We performed PCR to amplify the genomic DNA fragments containing the different representative tRNAs using primer pairs (Table S1 and S2) and genomic DNA purified from HEK 293T as templates. The amplified PCR fragments were cloned into pGEM-T Easy vector (Promega, USA), according to the manufacturer’s manual. A tRNA_Hum_GUC gene, which was presented in the old tRNA database (http://gtrnadb2009.ucsc.edu) but was removed out in the new database (http://gtrnadb.ucsc.edu), was designated as a pseudo gene.

Primary antibodies were purchased from Cell Signaling Technology (USA). The antibodies used were phosphor (P)-p70 S6K (#9206), S6K (#9202), P-p90-RSK (#9341), P-MSK (#9591), RSK1/RSK2/RSK3 (#9355), MSK2 (#3679), P-ERK1/2 (#9101), and P-SAPK/JNK (#4668). Anti-tubulin antibody (T-5168) was purchased from Sigma-Aldrich (USA). Secondary antibodies, goat anti-rabbit (31460) and goat anti-mouse (Cat. 31430), were purchased from Thermo Fisher Scientific (USA).

**Cell culture, tRNA transfection, and kinase inhibitor treatment**

HEK293T, NIH3T3 MEF, CCD18C0, HT29, BT20, MCF7, WI-26, and HCC2279 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% (100 μg/ml) penicillin and streptomycin (PS) at 37°C in a 5% CO₂ incubator. For culturing HCT8, NHA, LN18, U343, U87E4, MDA-MB-231, A549, and H460, RPMI 1640 medium with 10% FBS and 1% PS was used. MCF10A and M13SV1 cells were cultured in media described elsewhere, and SW620J cells were cultured in Leibovitz’s L-15 medium with 10% FBS and 1% PS. For depletion of methionine, we purchased all the culture media and supplements from Hyclone (USA) and amino acid- or leucine-free media from Welgene Inc. (Korea).

HEK 293T cells were transfected with tRNA-expressing pGEM-T Easy vector using Fugene reagent (Promega, USA) for 24 h. HEK 293T cells were pre-incubated in the amino acid-deprivation medium for 3 h and then treated with rapamycin (100 nM), U0126 (ERK inhibitor) (20 mM), SP600125 (JNK inhibitor) (20 mM), and SB203580 (p38 MAPK) (20 mM) for an additional 1.5 h. All the inhibitors were purchased from Calbiochem (USA).

**Real-time monitoring of cell proliferation**

HEK 293T cells were seeded in 48-well plates at a density of 6 x 10⁵ cells/well. The next day, cells were transfected with 0.5 μg each of tRNA-expressing pGEM-T Easy vector or EV, using Fugene reagent. Real-time growth was monitored using IncuCyte Live Cell Analysis System (Essen BioScience, USA). Complete medium in the 48-well plates was replaced with SF medium 12 h after transfection, which was then replaced with amino acid-free medium 10 h after the media change. Cells were incubated in the chamber for an additional two days, and cell growth was monitored during the whole incubation period.

**Stable cell line generation**

Plasmids that expressed tRNA_Leu_CAG (pHAG010) was prepared by cloning the following PCR products digested with Bgl II and Snal I into the pHAE057 plasmid that was prepared by replacing the pyrroymycin-resistant gene with the hygromycin-resistant gene and deleting the region between TRE and EGF from the pEM791 plasmid (obtained from Dr. Eugene V. Makeyev, Nanyang Technological University, Singapore). PCR was performed for the tRNA genes, using the forward primer (5'-CACAACAACAGATCTTATGCAGGCCG-3') and reverse primer (5'-TTTGCTGTCTACGTAGTGGCTAATAA-3').

Stable cell lines expressing tRNA were generated using recombination-mediated cassette exchange (RMCE) technology, as described previously. The pEM584 plasmid (kindly provided by Dr. Eugene V. Makeyev) was first transfected into the NIH3T3 cell line, and colonies resistant to blasticidin S (2.5 μg/ml) were isolated, expanded and used as a control. The genomes of these colonies integrated with the RMCE cassette that contained the human EF-1α promoter and a blasticidin resistance gene (Bsd) “floxed” by the mutually incompatible Cre recombinase-specific sites, Lox2272 and LoxP. The plasmid with the tRNA_Leu_CAG (pHAG010) was then co-transfected with pEM784 (pCAGGS-nLCre) into the blasticidin S-resistant cell lines, and colonies resistant to hygromycin (100 μg/ml) and sensitive to blasticidin S were selected.
**Thymidine incorporation**

H460 cells were transfected with different tRNA isotopes and 12 h later, cells (5 x 10^5) were seeded on 24-well dishes. After 12 h, [3H]thymidine (1 μCi/well, PerkinElmer, USA) was added to the wells and incubated for 4 h. Cells were washed thrice with cold PBS and then treated with 5% cold trichloroacetic acid for 10 min. DNA was then extracted with 0.5 M NaOH and the incorporated thymidine was quantified with a liquid scintillation counter (Wallac, PerkinElmer).

**Methionine incorporation assay**

H460 cells were transfected with different tRNA isotopes. After incubating in a methionine-free medium (Hyclone) for 30 min, 1 μCi [35S]Met (1175 Ci/mmol, PerkinElmer, USA) was added. After 1 h incubation, cells were washed thrice with cold PBS and the radioactive protein was quantified using a liquid scintillation counter and normalized based on cell number.

**Cell cycle analysis with FACS**

The cells transfected with each tRNA were harvested by trypsinisation, washed twice with cold PBS, and fixed in 70% ethanol for 2 h at 4°C. After fixation, the cells were washed twice with cold PBS and incubated in 500 μl PI (propidium iodide, Sigma-Aldrich) staining solution (1 x PBS, 100 μg/ml RNase A, and 50 μg/ml PtdIns) for 30 min at 37°C in the dark. The samples were analyzed by flow cytometry (BD Biosciences, USA). The percentage of cells in the G0/G1, S, and G2/M phases was estimated using the Cell Quest acquisition software (BD Biosciences).

**Gel electrophoresis and immunoblotting**

HEK293T cells were lysed with a protein lysis buffer (25 mM Tris-HCl pH 7.4, 0.5% Tripton X-100, 1 mM EDTA, 0.5 mM EGTA, 10 mM NaCl, 1 mM MgCl2, and 0.1% CHAPS) containing phosphatase inhibitor and protease inhibitor (Calbiochem) for 30 min at 4°C. After lysis and protein concentration measurement, the proteins were separated by SDS-PAGE. The proteins were then semi-dry transferred to polyvinylidenefluoride membranes (Millipore, USA), which were subjected to immunoblotting.

**Northern blotting**

Total RNA (30 μg) was isolated from tRNA-transfected HEK 293T or HeLa cells with the miRNeasy Mini Kit (Qiagen, USA) and then separated with 6.5% PAGE with 8% urea in 0.5% TBE buffer. After EtBr (ethidium bromide) staining, the gel was transferred onto a nylon membrane with a semi-dry transfer apparatus. The 3' and 5' end-specific probes were generated by end-labeling of the DNA oligonucleotides with [γ-32P]ATP using T4 polynucleotide kinase (NEB, USA). Northern hybridization was performed using the BrightStar BioDetect kit (Ambion, USA), and the result was exposed for autoradiography. The sequences of the probes were as follows: Leu(CAG) 3' end probe, 5'-CAGCGCCCTTAGACCGCTCGGCCATCCTCGA C-3'; Leu(CAG) 3' end probe, 5'-TGGTGTCAGAGTGG-GATTGAACCACCCG-3'; Leu(UAG) 5' end probe, 5'-CAGC GCTTGAAGCCTCGGCCACACTAC-3'; Leu(UAG) 3' end probe, 5'-TGGTGCCAGTGGGATTCGAAACCAGC-3'; Leu(AAG) 5' end probe, 5'-CAGCGCGCTTAGAGGCTCGG- C-3'; and Leu(AAG) 3' end probe, 5'-TGGTGCGACGGGATTCGAAACCAGC-3'.

**Semi-quantitative RT-PCR**

Total RNA was extracted with miRNeasy Mini kit (Qiagen). From the immunoprecipitated sample, RNA was extracted using the TRizol reagent (Thermo Fisher). The RNA (2 μg) was reverse-transcribed using M-MLV reverse transcriptase (RT), a random hexamer, dNTP, DTT, and reaction buffer. The mixture was heated at 65°C for 5 min, followed by heating at 37°C for 2 min, 25°C for 10 min, 37°C for 50 min, and finally at 70°C for 15 min. For measuring the overexpressed tRNAs, cDNA was amplified by PCR using specific primers (Table S2) and Taq polymerase under the following thermocyclic conditions: one cycle for denaturing at 95°C for 5 min; 30 cycles of amplification at 95°C for 1 min, 60°C for 30 sec, and 72°C for 30 sec; and one cycle of extension at 72°C for 10 min. The amplified PCR products were separated by electrophoresis on a 6% native polyacrylamide gel with 0.5 x TBE.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)**

Total RNA extraction and cDNA generation were performed as described in previous sections. The transcript levels of tRNAs (target) and GAPDH and Papola (endogenous references) were determined by qRT-PCR using the POWER SYBR green master mix (Bio-rad) and specific primers (Table S2), according to the manufacturers’ instructions. The fold change of each target or -ΔΔCt were presented relative to those of control samples.

**RNA interference**

For the siRNA experiments, transfection of siRNA was performed using the lipofectamine 2000 transfection reagent (Invitrogen, USA), according to the manufacturer’s guidelines. HEK 293T cells were transfected with siRNA for 48 h. A stealth RNAi negative control, medium GC duplexes (Invitrogen), was used as a control. For knocking down the RSK and MSK genes, siRNA negative control, medium GC duplexes (Invitrogen), was used as a control. For knocking down the RSK and MSK genes.
In vitro transcription of tRNA and in vitro aminoacylation using flexizyme

The pGEM-T Easy plasmids containing the tRNA$^{\text{Leu}_{\text{CAG}}}$ sequences were used as templates and amplified by PCR for the in vitro transcription of tRNA sequences using corresponding primer pairs (Table S2) and Pfu polymerase. After gel extraction, in vitro transcription was performed using the Riboprobe® in vitro Transcription Systems (Promega). The residual DNA was digested using Dnase I, and the tRNAs were purified by phenol/chloroform precipitation. After rehydration with RNase-free distilled water (DW), tRNA was eluted using Illustra NAP columns (GE Healthcare, USA).

For the in vitro biotinylation of the synthesized tRNA, we generated eFx flexizyme, according to the protocol described previously, and thus charged the synthesized tRNA with biotin-Phe-DBE.

Gel shift assay

The mixture of in vitro synthesized tRNA and siRNA was pre-incubated at 70°C for 5 min, slowly cooled down to promote secondary structure formation, and then further incubated at 30°C for 30 min. The tRNA and siRNA mixture was separated by a 6% non-denaturing PAGE with 0.5 x TBE (tris borate EDTA) buffer and stained with EtBr.

For analyzing the tRNA and EBPI complex, the tRNA was synthesized in vitro using [α-32P]ATP and incubated with EBPI (Sino Biological, China) at 30°C for 30 min. The reaction mixture was then separated by 6% non-denaturing PAGE with 4% urea in 0.5% TBE buffer. After running the gel, it was dried and exposed for autoradiography.

SILAC and LC-MS/MS analysis

For SILAC mass spectrometry, HEK 293T cells were cultured in the different SILAC media (DMEM without L-arginine and L-lysine (Invitrogen) with 10% dialyzed FBS and 1% PS containing 50 mg/ml L-arginine (Arg0) and L-lysine (Lys0) (light), or 13C6L5N4-L-arginine (Arg10) and 13C6L5N2-L-Lysine (Lys8) (heavy) for 7 d (at least 5 passages). After amino acid starvation for 1.5 h, cells were lysed in a buffer (50 mM Tris-HCl [pH 8.0], 150 mM KCl, 1 mM DTT, 10% glycerol, and 0.5% Triton X-100) at 4°C for 30 min. After centrifugation at 10,000 x g for 15 min, the total cell extract was added to the biotinylated tRNA$^{\text{Leu}_{\text{CAG}}}$, which was immobilized on streptavidin beads. After incubation with constant rotation at 4°C for 4 h, streptavidin-conjugated agarose beads (GE Healthcare) were added and further incubated at 4°C for 2 h. The beads were washed twice with 300 mM KCl buffer (20 mM Tris-Cl [pH 8.0], 300 mM KCl, and 0.2 mM EDTA). The proteins were eluted using a 2 x SDS sample buffer and separated with SDS-PAGE. The areas of the gel with the whole protein were cut into several pieces and were subjected to in-gel digestion with trypsin (Promega). LC-MS/MS analysis of eluted peptides was performed by a linear trap quadrupole (LTQ)-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific).

All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, version 1.3.0.339). Sequest was set up to search into the Peptide Prophet algorithm. If they could be established at greater than 95.0% probability by the Peptide Prophet algorithm, Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Normalization was performed iteratively (across samples and spectra) by subtracting the average ratios in log-space. Means were used for averaging. Spectra data were log-transformed, pruned of those matched to multiple proteins, and weighted by an adaptive intensity-weighting algorithm. Of 7,915 spectra in the experiment at the given thresholds, 3,430 (43%) were included in quantitation.

Population of patients with breast cancer and immunohistochemistry staining

Patients diagnosed with primary tumors of the breast and with available clinical and pathological data were selected for this study. Immunohistochemical assessment of estrogen receptor (ER) and progesterone receptor (PR) were performed by an experienced pathologist, using antibodies against ER (1DO5; DAKO, Denmark) and PR (PgR626, DAKO), respectively. The HER2 membranous staining was scored on a scale of 0 to 3+, according to the HercepTest protocol (DAKO). For tissue samples with a HER2 staining score of 2+, additional testing for HER2 was performed using fluorescence in situ hybridization (FISH). The HER2 status was considered positive if the IHC score was 3+ or the gene copy ratio of HER2/CEP17 was more than 2.2.

Tumor samples

Ninety-five primary tumor samples were obtained from breast cancer surgical specimens immediately after resection. Tumor blocks were harvested in gross from the tumor cores and stored in nitrogen tanks at a tissue bank (Laboratory of Breast Cancer Biology, Seoul National University College of Medicine, Seoul, Korea). Informed consent was obtained from all the participants before sampling, and the study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No 1405–088–580, 1704–051–844). Total RNA was extracted from the tissues and used for the analysis of tRNA$^{\text{Leu}_{\text{CAG}}}$ isotypes by qRT-PCR, as mentioned in previous sections.

Statistical analysis of patient data

Independent t-tests and one-way ANOVA analyses were performed to compare the average amounts of tRNA$^{\text{Leu}_{\text{CAG}}}$ isotypes
for the different experiments. All statistical analyses were performed using the SPSS Version 23.0 software. Statistical significance was assumed if $P < 0.05$.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

This research was jointly supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare [HI13C21480301 [N.H.K.]], the Global Frontier (NRF-D3A6A-4-2010–0029785 [S.K.] and NRF-2015M3A6A4065724 [N.H.K.]) National Research Foundation funded by the Ministry of Science, ICT & Future Planning (MSIP) of Korea, and a grant from Gyeonggi Research Development Program [S.K.].

We would like to thank Dr. Horoaki Suga for sharing the materials required for eFx synthesis and in vitro biotinylation of tRNA and Dr. Eugene V. Makeyev for providing pEM791 and pEMS84 plasmids.

**References**

1. Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: More than housekeeping. Nat Rev Cancer. 2011;11:708-718. doi:10.1038/nrc3124

2. Iben JR, Maraiia RJ. tRNA gene copy number variation in humans. Gene. 2014;536:376-384. doi:10.1016/j.gene.2013.11.049

3. Goodenour JM, Pan T. Diversity of tRNA genes in eukaryotes. Nucleic Acids Res. 2006;34:6137-6146. doi:10.1093/nig/ikk725

4. Goodarzi H, Nguyen HC, Zhang S, Dill BD, Molina H, Tavazoie SF. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell. 2016;165:1416-1427. doi:10.1016/j.cell.2016.05.046

5. Mei Y, Yong J, Liu H, Shi Y, Meinloth J, Dreyfuss G, Yang X. tRNA binds to cytochrome c and inhibits caspase activation. Mol Cell. 2010;37:668-678. doi:10.1016/j.molcel.2010.01.023

6. Birch J, Clarke CJ, Campbell AD, Campbell K, Mitchell L, Liko D, Kalna G, Strathdee D, Sansom OJ, Neilson M, et al. The initiator methionine tRNA drives cell migration and invasion leading to increased metastatic potential in melanoma. Biol Open. 2016;5:1371-1379. doi:10.1242/bio.019075

7. Pavon-Eternod M, Gomes S, Rosner MR, Pan T. tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res. 2009;37:7268-7280. doi:10.1093/nar/gkp787

8. Marshall L, White RJ. Non-coding RNA production by RNA polymerase III is implicated in cancer. Nat Rev Cancer. 2008;8:911-914. doi:10.1038/nrc2539

9. Zouridis H, Hatzimanikatis V. Effects of codon distributions and tRNA competition on protein translation. Biophys J. 2008;95:1018-1033. doi:10.1529/biophysj.107.126128

10. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22:346-353. doi:10.1016/j.tibtech.2004.04.006

11. dos Reis M, Savva R, Wernisch L. Solving the riddle of codon usage preferences: A test for translational selection. Nucleic Acids Res. 2004;32:5036-5044. doi:10.1093/nar/gkh834

12. Qian W, Yang JR, Pearson NM, Maclean C, Zhang J. Balanced codon usage optimizes eukaryotic translational efficiency. PLoS Genet. 2012;8:e1002603. doi:10.1371/journal.pgen.1002603

13. Subramaniam AR, Pan T, Cluzel P. Environmental perturbations lift the degeneracy of the genetic code to regulate protein levels in bacteria. Proc Natl Acad Sci U S A. 2013;110:2419-2424. doi:10.1073/pnas.1211077110

14. Gingold H, Tehler D, Christoffersen NR, Nielsen MM, Asmar F, Kooistra SM, Christophersen NS, Christensen LL, Borre M, Sørensen KD, et al. A dual program for translation regulation in cellular proliferation and differentiation. Cell. 2014;158:1281-1292. doi:10.1016/j.cell.2014.08.011

15. Berven LA, Crouch MF. Cellular function of p70S6K: A role in regulating cell motility. Immunol Cell Biol. 2000;78:447-451. doi:10.1038/1440-1711.2000.00928.x

16. Casas-Terradellas E, Tato I, Bartrons R, Ventura F, Rosa JL. ERK and p38 pathways regulate amino acid signalling. Biochim Biophys Acta. 2008;1783:2241-2254. doi:10.1016/j.bjabc.2008.08.011

17. Reinhard C, Thomas G, Kozma SC. A single gene encodes two isoforms of the p70 S6 kinase: Activation upon mitogenic stimulation. Proc Natl Acad Sci U S A. 1992;89:4052-4056. doi:10.1073/pnas.89.9.4052

18. Geiduschek EP, Kassavetis GA. The RNA polymerase III transcription apparatus. J Mol Biol. 2001;310:1-26. doi:10.1006/jmbi.2001.4732

19. Dieci F, Giorino G, Castelnuovo M, Teichmann M, Pagano A. The expanding RNA polymerase III transcriptome. Trends Genet. 2007;23:614-622. doi:10.1016/j.tig.2007.09.001

20. Sharma U, Conine CC, Shea JM, Boskovic A, Derr AG, Bing XY, Bellannee C, Kucukural A, Serra RW, Sun F, et al. Biogenesis and function of tRNA fragments during sperm maturation and fertilization in mammals. Science. 2016;351:391-396. doi:10.1126/science.aad6780

21. Leung JM, Shilata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23:2639-2649. doi:10.1101/gad.1837609

22. Finger DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-3171. doi:10.1038/sj.onc.1207542

23. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589-3594. doi:10.1242/jcs.051011

24. Meijer AJ, Codogno P. Nutrient sensing: TOR’s rampage. Nat Cell Biol. 2008;10:881-883. doi:10.1038/ncc0808-881

25. Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012;149:410-424. doi:10.1016/j.cell.2012.02.044

26. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23:2639-2649. doi:10.1101/gad.1837609

27. Lee JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012;149:410-424. doi:10.1016/j.cell.2012.02.044

28. Lee JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012;149:410-424. doi:10.1016/j.cell.2012.02.044

29. Ichida J, Hanada T, Weitzer S, Mair B, Bernreuther C, Wainger BJ. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell. 2016;165:18201-18206. doi:10.1073/pnas.1407361111

30. Maraiia RJ. Small nucleolar RNA metabolism to progressive motor-neuron loss. Nature. 2016;351:391-396. doi:10.1038/nrc3124

31. Makeyev EV. tRNA-derived small RNAs in the global regulation of RNA silencing. RNA. 2010;16:673-695. doi:10.1261/rna.2000810
37. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell. 2015;161:790-802. doi:10.1016/j.cell.2015.02.053

38. Lara R, Seckl MJ, Pardo OE. The p90 RSK family members: Common functions and isoform specificity. Cancer Res. 2013;73:5301-5308. doi:10.1158/0008-5472.CAN-12-4448

39. Anjum R, Blenis J. The RSK family of kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9:747-778. doi:10.1038/nrm2509

40. Goto Y, Katoh T, Suga H. Flexizymes for genetic code reprogramming. Nat Protoc. 2011;6:779-790. doi:10.1038/nprot.2011.331

41. Zhang Y, Hamburger AW. Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription. J Biol Chem. 2004;279:26126-26133. doi:10.1074/jbc.M314305200

42. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413-448. doi:10.1038/cgt.2008.15

43. Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Goodfellow IG, Curry S. Structural insights into the transcriptional and translational roles of Ebp1. EMBO J. 2007;26:3936-3944. doi:10.1038/sj.emboj.7601817

44. Zhang Y, Akinmade D, Hamburger AW. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett. 2008;265:298-306. doi:10.1016/j.canlet.2008.02.024

45. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995;15:6496-6505. doi:10.1128/MCB.15.12.6496

46. Khandelia P, Yap K, Makeyev EV. Streamlined platform for short hairpin RNA interference and transgenesis in cultured mammalian cells. Proc Natl Acad Sci U S A. 2011;108:12799-12804. doi:10.1073/pnas.1103532108

47. Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretiere JM, Ricevuto E, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res. 2008;68:6092-6099. doi:10.1158/0008-5472.CAN-08-0436

48. Lee KS, Koo JY, Chung HC, Suh CO, Lee HD, Lee BC, Jung WH, Yang WL. Immunohistochemical expression of c-erbB2, c-erbB3 and c-erbB4 protein in breast cancer. J Korean Breast Cancer Soc. 1998;1:215-225. doi:10.4048/jkbsc.1998.1.2.1215

49. Kirchner S, Ignatova Z. Emerging roles of tRNA in adaptive translation, signalling dynamics and disease. Nat Rev Genet. 2015;16:98-112. doi:10.1038/nrg3861

50. Karakozova M, Kozak M, Wong CC, Bailey AO, Yates JR, Mogilner A 3rd, Zebroski H, Kashina A. Arginylation of beta-actin regulates actin cytoskeleton and cell motility. Science. 2006;313:192-196. doi:10.1126/science.1129344

51. Jahn D, Verkamp E, Soll D. Glutamyl-transfer RNA: A precursor of heme and chlorophyll biosynthesis. Trends Biochem Sci. 1992;17:215-218. doi:10.1016/0968-0004(92)90080-R

52. Roy H, Ibbma M. RNA-dependent lipid remodeling by bacterial multiple peptide resistance factors. Proc Natl Acad Sci U S A. 2008;105:4667-4672. doi:10.1073/pnas.080006105

53. Miller SB, Yildiz FZ, Lo JA, Wang B, D’Souza VM. A structure-based mechanism for tRNA and retroviral RNA remodelling during primer annealing. Nature. 2014;515:591-595. doi:10.1038/nature13709

54. Ruggiero K, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanolvello P, Bronte V, Cinimale V, et al. Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: A role for a tRNA fragment as a primer for reverse transcriptase. J Virol. 2014;88:3612-3622. doi:10.1128/JVI.02823-13

55. Rudinger-Thirion J, Lesecure A, Paulus C, Frugier M. Misfolded human tRNA isodecoder binds and neutralizes a 3' UTR-embedded Alu element. Proc Natl Acad Sci U S A. 2011;108:E794-802. doi:10.1073/pnas.1103698108

56. Soma A, Himeno H. Cross-species aminoacylation of tRNA with a long variable arm between Escherichia coli and Saccharomyces cerevisiae. Nucleic Acids Res. 1998;26:4374-4381. doi:10.1093/nar/26.19.4374

57. Moon A, Kim MS, Kim TG, Kim HE, Chen YQ, Kim HR. Hras, but not Nras, induces an invasive phenotype in human breast epithelial cells: A role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer. 2000;85:176-181. doi:10.1002/(SICI)1097-0215(20000115)85:2%3C176::AID-IJC2%3E3.0.CO;2-E

58. Keller A, Nesvizhskii AI, Keller A, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002;74:5383-5392. doi:10.1021/ac020574h

59. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003;75:4646-4658. doi:10.1021/ac0341261